| 1. Morgan J, Haritakul R, Keller PA.. (2003) Anilinopyrimidines as novel antituberculosis agents., 13 (10): [PMID:12729658] [10.1016/s0960-894x(03)00241-5] |
| 2. O'Sullivan JF, Conalty ML, Morrison NE.. (1988) Clofazimine analogues active against a clofazimine-resistant organism., 31 (3): [PMID:3279207] [10.1021/jm00398a013] |
| 3. Cianchetta G, Singleton RW, Zhang M, Wildgoose M, Giesing D, Fravolini A, Cruciani G, Vaz RJ.. (2005) A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR., 48 (8): [PMID:15828831] [10.1021/jm0491851] |
| 4. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG.. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis., 51 (4): [PMID:17210775] [10.1128/aac.00055-06] |
| 5. Doak AK, Wille H, Prusiner SB, Shoichet BK.. (2010) Colloid formation by drugs in simulated intestinal fluid., 53 (10): [PMID:20426472] [10.1021/jm100254w] |
| 6. PubChem BioAssay data set, |
| 7. PubChem BioAssay data set, |
| 8. PubChem BioAssay data set, |
| 9. Ramón-García S, Martín C, Thompson CJ, Aínsa JA.. (2009) Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth., 53 (9): [PMID:19564371] [10.1128/aac.00550-09] |
| 10. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 11. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 12. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.. (2008) Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models., 18 (2): [PMID:20020916] [10.1080/15376510701857262] |
| 13. Unpublished dataset, |
| 14. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 15. PubChem BioAssay data set, |
| 16. Wang EJ, Casciano CN, Clement RP, Johnson WW.. (2003) Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites., 20 (1): [PMID:12739759] [10.1023/a:1023278211849] |
| 17. Wang EJ, Casciano CN, Clement RP, Johnson WW.. (2001) Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors., 289 (1): [PMID:11716514] [10.1006/bbrc.2001.6000] |
| 18. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 19. Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, Zhang H, Liu Y, Wang B, Zheng M, Fu L, Hou Y, Gong N, Lv Y, Li C, Cooper CB, Upton AM, Yin D, Ma Z, Huang H.. (2012) Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis., 55 (19): [PMID:22931472] [10.1021/jm300828h] |
| 20. Dartois V, Barry CE.. (2013) A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis., 23 (17): [PMID:23910985] [10.1016/j.bmcl.2013.07.006] |
| 21. Cai G, Napolitano JG, McAlpine JB, Wang Y, Jaki BU, Suh JW, Yang SH, Lee IA, Franzblau SG, Pauli GF, Cho S.. (2013) Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain., 76 (11): [PMID:24224794] [10.1021/np400145u] |
| 22. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 23. PubChem BioAssay data set, |
| 24. Heine D, Martin K, Hertweck C.. (2014) Genomics-guided discovery of endophenazines from Kitasatospora sp. HKI 714., 77 (4): [PMID:24617951] [10.1021/np400915p] |
| 25. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 26. Karabanovich G, Roh J, Smutný T, Němeček J, Vicherek P, Stolaříková J, Vejsová M, Dufková I, Vávrová K, Pávek P, Klimešová V, Hrabálek A.. (2014) 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria., 82 [PMID:24927053] [10.1016/j.ejmech.2014.05.069] |
| 27. Barteselli A, Casagrande M, Basilico N, Parapini S, Rusconi CM, Tonelli M, Boido V, Taramelli D, Sparatore F, Sparatore A.. (2015) Clofazimine analogs with antileishmanial and antiplasmodial activity., 23 (1): [PMID:25497962] [10.1016/j.bmc.2014.11.028] |
| 28. Tonelli M, Novelli F, Tasso B, Sparatore A, Boido V, Sparatore F, Cannas S, Molicotti P, Zanetti S, Parapini S, Loddo R.. (2014) Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines., 22 (24): [PMID:25464882] [10.1016/j.bmc.2014.10.035] |
| 29. Poce G, Cocozza M, Consalvi S, Biava M.. (2014) SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development., 86 [PMID:25173852] [10.1016/j.ejmech.2014.08.066] |
| 30. Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning, [10.6019/CHEMBL3392926] |
| 31. Bellera CL, Balcazar DE, Vanrell MC, Casassa AF, Palestro PH, Gavernet L, Labriola CA, Gálvez J, Bruno-Blanch LE, Romano PS, Carrillo C, Talevi A.. (2015) Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir., 93 [PMID:25707014] [10.1016/j.ejmech.2015.01.065] |
| 32. MMV Pathogen Box, [10.6019/CHEMBL3637841] |
| 33. Abraham RJ, Stevens AJ, Young KA, Russell C, Qvist A, Khazandi M, Wong HS, Abraham S, Ogunniyi AD, Page SW, O'Handley R, McCluskey A, Trott DJ.. (2016) Robenidine Analogues as Gram-Positive Antibacterial Agents., 59 (5): [PMID:26765953] [10.1021/acs.jmedchem.5b01797] |
| 34. Karabanovich G, Zemanová J, Smutný T, Székely R, Šarkan M, Centárová I, Vocat A, Pávková I, Čonka P, Němeček J, Stolaříková J, Vejsová M, Vávrová K, Klimešová V, Hrabálek A, Pávek P, Cole ST, Mikušová K, Roh J.. (2016) Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis., 59 (6): [PMID:26948407] [10.1021/acs.jmedchem.5b00608] |
| 35. WHO Anatomical Therapeutic Chemical Classification, |
| 36. British National Formulary (72nd edition), |
| 37. Anna Ehmann. The Australian National University Dept Of Immunology Pathogen Box Compounds Screened, [10.6019/CHEMBL3987221] |
| 38. Karabanovich G, Němeček J, Valášková L, Carazo A, Konečná K, Stolaříková J, Hrabálek A, Pavliš O, Pávek P, Vávrová K, Roh J, Klimešová V.. (2017) S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents., 126 [PMID:27907875] [10.1016/j.ejmech.2016.11.041] |
| 39. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development., 118 (2): [PMID:20829430] [10.1093/toxsci/kfq269] |
| 40. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.. (2014) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump., 60 (3): [PMID:24799086] [10.1002/hep.27206] |
| 41. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 42. Roh J, Karabanovich G, Vlčková H, Carazo A, Němeček J, Sychra P, Valášková L, Pavliš O, Stolaříková J, Klimešová V, Vávrová K, Pávek P, Hrabálek A.. (2017) Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents., 25 (20): [PMID:28835350] [10.1016/j.bmc.2017.08.010] |
| 43. Unpublished dataset, |
| 44. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 45. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek. (2020) Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection, [10.21203/rs.3.rs-23951/v1] |
| 46. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 47. Sbaraglini ML, Bellera CL, Quarroz Braghini J, Areco Y, Miranda C, Carrillo C, Kelly J, Buchholz B, Gelpi RJ, Talevi A, Alba Soto CD.. (2019) Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease., 184 [PMID:31630056] [10.1016/j.ejmech.2019.111778] |
| 48. Karabanovich G, Dušek J, Savková K, Pavliš O, Pávková I, Korábečný J, Kučera T, Kočová Vlčková H, Huszár S, Konyariková Z, Konečná K, Jand'ourek O, Stolaříková J, Korduláková J, Vávrová K, Pávek P, Klimešová V, Hrabálek A, Mikušová K, Roh J.. (2019) Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase., 62 (17): [PMID:31393122] [10.1021/acs.jmedchem.9b00912] |
| 49. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 50. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 51. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 52. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 53. Sarink, M; Mykytyn, A; Tielens, A; van Hellemond, J. Naegleria gruberi Pathogen Box compounds screening, [10.6019/CHEMBL4513101] |
| 54. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection, [10.6019/CHEMBL4513141] |
| 55. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of MMV (CH) - MMV compounds, [10.6019/CHEMBL4513149] |
| 56. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of MMV (CH) - Pandemic Response Box, [10.6019/CHEMBL4513161] |
| 57. Bera S, Mondal D.. (2019) Insights of synthetic analogues of anti-leprosy agents., 27 (13): [PMID:31103404] [10.1016/j.bmc.2019.04.032] |
| 58. Makarov V, Salina E, Reynolds RC, Kyaw Zin PP, Ekins S.. (2020) Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis., 63 (17): [PMID:32259446] [10.1021/acs.jmedchem.9b02075] |
| 59. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 60. Ghahremanpour MM,Tirado-Rives J,Deshmukh M,Ippolito JA,Zhang CH,Cabeza de Vaca I,Liosi ME,Anderson KS,Jorgensen WL. (2020) Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2., 11 (12.0): [PMID:33324471] [10.1021/acsmedchemlett.0c00521] |
| 61. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 62. Koval A, Bassanini I, Xu J, Tonelli M, Boido V, Sparatore F, Amant F, Annibali D, Leucci E, Sparatore A, Katanaev VL.. (2021) Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo., 222 [PMID:34116325] [10.1016/j.ejmech.2021.113562] |
| 63. Fridianto KT, Li M, Hards K, Negatu DA, Cook GM, Dick T, Lam Y, Go ML.. (2021) Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against Mycobacterium tuberculosis., 64 (21.0): [PMID:34706190] [10.1021/acs.jmedchem.1c01383] |
| 64. Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR, Valdameri G.. (2022) Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators., 237 [PMID:35483322] [10.1016/j.ejmech.2022.114346] |
| 65. Fernandes GFS, Thompson AM, Castagnolo D, Denny WA, Dos Santos JL.. (2022) Tuberculosis Drug Discovery: Challenges and New Horizons., 65 (11.0): [PMID:35612311] [10.1021/acs.jmedchem.2c00227] |
| 66. Zhang X, Shi Y, Guo Z, Zhao X, Wu J, Cao S, Liu Y, Li Y, Huang W, Wang Y, Liu Q, Li Y, Song D.. (2022) Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism., 234 [PMID:35279610] [10.1016/j.ejmech.2022.114209] |
| 67. Pillaiyar T, Meenakshisundaram S, Manickam M, Sankaranarayanan M.. (2020) A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery., 195 [PMID:32283298] [10.1016/j.ejmech.2020.112275] |
| 68. Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK.. (2017) Drug development against tuberculosis: Impact of alkaloids., 137 [PMID:28628823] [10.1016/j.ejmech.2017.06.005] |
| 69. Kumar G, Kapoor S.. (2023) Targeting mycobacterial membranes and membrane proteins: Progress and limitations., 81 [PMID:36804747] [10.1016/j.bmc.2023.117212] |
| 70. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
